MPYS protein inhibitors - Pipeline Insight, 2024

MPYS protein inhibitors - Pipeline Insight, 2024

DelveInsight’s, “MPYS protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MPYS protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

MPYS protein inhibitors Understanding

MPYS protein inhibitors: Overview

Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS is a protein that in humans is encoded by the STING1 gene. STING plays an important role in innate immunity. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferon, mediated by STING, protects infected cells and nearby cells from local infection by binding to the same cell that secretes it (autocrine signaling) and nearby cells (paracrine signaling. It thus plays an important role, for instance, in controlling norovirus infection.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence MPYS protein inhibitors R&D. The therapies under development are focused on novel approaches for MPYS protein inhibitors.

MPYS protein inhibitors Emerging Drugs Chapters

This segment of the MPYS protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

MPYS protein inhibitors Emerging Drugs

• Veyonda: Noxopharm

Noxopharm's lead drug candidate is called Veyonda® (also known as NOX66) which is being developed as a treatment for cancer and has already advanced to phase 2 clinical trials. It is also being investigated as a treatment for septic shock. As a cancer treatment, Veyonda® is a first-in-class, dual-acting oncotoxic and immuno-modulatory drug candidate designed to enhance the effectiveness and safety of chemotherapy, radiotherapy and immuno-oncology therapy.

• SB 11736: AstraZeneca

In August 2019, Spring Bank entered into a research agreement with the University of Texas Southwestern Medical School to evaluate its small molecule STING antagonist compounds. SB 11736 is an orally-available STING antagonist.

Further product details are provided in the report……..

MPYS protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different MPYS protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on MPYS protein inhibitors

There are approx. 4+ key companies which are developing the MPYS protein inhibitors. The companies which have their MPYS protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Noxopharm.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

MPYS protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

MPYS protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MPYS protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MPYS protein inhibitors drugs.

MPYS protein inhibitors Report Insights

• MPYS protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

MPYS protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing MPYS protein inhibitors drugs?
• How many MPYS protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MPYS protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MPYS protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for MPYS protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Noxopharm
• AstraZeneca
• F-star Therapeutics
• Chinook Therapeutics
• Bayer
• Nimbus Therapeutics
• Mavupharma

Key Products

• Veyonda
• SB 11736
• cGAS-STING pathway inhibitor program
• Research programme: STING antagonists
• Research programme: small molecule MPYS protein inhibitors
• MAVU 104